

The logo for amoéba features a stylized circular shape composed of three overlapping segments: a blue segment at the top, a green segment on the right, and a lime green segment at the bottom. A thin white horizontal line passes through the center of the logo and the text.

amoéba

GENERAL MEETING

JUNE, 26 2025



26 June 2025 | Presentation of the General Meeting


# AMOÉBA CHRONOLOGY

## From an R&D company to a Commercialization company



# A TECHNOLOGICAL PLATFORM WITH MULTIPLE APPLICATIONS


## 2 pre-marketing ranges





# WE WILL BE SOON READY TO PLAY GRAND SLAM

## Projected timetable for approval on main areas



# AXPERA

## Our range of solutions for the transition from chemical to organic production

### Positive impact on agriculture



A highly competitive level of **performance**, demonstrated by over 600 field trials carried out in 19 countries

**A natural product** that meets the requirements of sustainable agriculture for **a wide range of crops**:



- Under glass: tomatoes, cucumbers, etc.
- Open fields: vines, soya, etc.
- Public areas: golf courses, gardens ...



European **market** estimated at **€1.6 billion**, growing at +/- 10% / year and US market estimated at **€3 billion**, growing at +/- 15% / year until 2030

### Market launch for 2025-2026



#### Regulatory

Positive and definitive conclusions on the active substance in the United States and Europe.

Final approval by the European Commission in June 2025.

Final assessment of the product by the competent authorities in France and other European countries is expected in late 2025/early 2026.



#### Production

Gradual increase in production capacity (from 0.4 to 1 tonne) at Chassieu for commercial launch and through CDMO (production partnership) partners.



#### Distribution

Signature of a major distribution agreement with Koppert

# FINAL APPROVAL BY THE EUROPEAN COMMISSION

A determining milestone is now completed



The European Food Safety Authority (EFSA) is one of the European Union's main agencies responsible for risk assessment in the field of foodstuffs.

In **June 2025**, the European Commission announced the final approval of “*Lysate of Willaertia magna*”.

## What are the key points about our active substance?

- ✓ Proven fungicidal efficacy;
- ✓ A low-risk profile for human and animal health, as well as for ecosystems and environmental organisms;
- ✓ A sustainable development approach;
- ✓ The criteria for exemption from a maximum residue level have been met.

**Final assessment of the product by the competent authorities in France and other European countries is expected in late 2025/early 2026.**



# AMOÉBA x KOPPERT (1/2)

## Signature of a major distribution agreement with a world leader in biocontrol

### The start of a collaboration with a world leader in biocontrol

Koppert offers "a system of specialist knowledge and safe natural solutions to improve the health, resistance and production of crops".



### Why partner together ?

- ✓ **Mutual expertise:** Koppert, a global leader in biocontrol, has conducted a thorough due diligence of Amoéba over two years trials, confirming the efficacy of its solutions.
- ✓ **Perfect synergy:** Amoéba's innovative fungicides complement Koppert's portfolio.
- ✓ **Shared vision:** Both companies are driven by innovation, sustainability, and natural ingredients.

**Together, we will leverage Koppert's 2,750 employees, 30 subsidiaries, 20% annual growth, and distribution in over 100 countries to deliver sustainable agricultural solutions worldwide.**



# AMOÉBA x KOPPERT (2/2)

## A new milestone for Amoéba



### Distribution

#### Exclusive distribution rights for Koppert during a period of 5 years

Vines and vegetable crops in greenhouses and open fields

18 European countries (France, the Netherlands, Germany, Italy...) and the US

Launch expected in 2026



### Co-development of new products

Launch of discussions on the co-development of new biofungicide solutions for the crops covered by the agreement

**Significant growth opportunities in the coming years**



### Production

*\*Contract Development  
Manufacturing Organizations*


Start with Amoéba's site in Chassieu (France)...

... and then scale up with European CDMO\* partner we already work with since 2024

# AND WE HAVE A POTENTIAL GAME-CHANGER...

## Short-term development: Launch of a biofertiliser innovation

Promising initial results :



### Corn model

With 100% treatment:

**+16%** length, **+42%** above-ground biomass and **+17%** root biomass

### Salad model

With 100% treatment:

**+46%** length, **+111%** above-ground biomass and **+58%** root biomass

An additional market segment to optimise the use of industrial equipment

**1kg**  
of active substance  
=  
**5 liters**  
of biocontrol  
+  
**95 liters**  
of biofertiliser

Simultaneously optimise revenue and production costs

Simplified regulatory process

Additional studies +/- 6 months

Launch potential: during 2026

# THE POTENTIAL OF BIOCONTROL HAS ONLY JUST BEGUN TO BE EXPLOITED

## Agreement with Koppert:

Vines and vegetable crops,  
across 18 European countries  
and the US

June 2025

Coming soon...

## Discussions engaged with Koppert and other actors

Crops (cereals, bananas, etc.) and/or  
geographical areas (Asia etc.)  
not covered by the agreement

Co-development of new  
products

Development  
potential for turf

Exploitation of effluent as bio-fertilizer




# SKIN PROTECTION (ANTI-AGEING / ANTI-UV)


A recent and promising innovation with proven effects

## October 2023 - Remarkable in-vitro studies

### Visible restoration of skin structure



Mature untreated skin




Mature skin **treated**

### Anti-ageing effect


	Filaggrin	Loricrin	Ki67	COL VII	HA (Dermis)	HA (Epidermis)	HA (Total skin)
Young skin	100	100	100	100	100	100	100
Aged skin	19	67	66	4	95	74	73
Treated aged skin	87	99	112	265	107	123	101

### Anti-UV effect

Young skin irradiated with UV



Young skin **treated** and then irradiated with UV light



# SKIN PROTECTION (ANTI-AGEING / ANTI-UV)

**A recent and promising innovation with proven effects**

## May 2024 – the clinical study confirms excellent in-vitro tests

**Results of** clinical trials justifying very strong claims in the field of anti-ageing cosmetics:

- "improvement in the thickness of the dermis"
- "repairing effect on the superficial dermis"
- "improved dermal texture"
- "improved skin density"
- "improved skin firmness and radiance"
- "improved skin texture and elasticity"
- "anti-wrinkle"

## Wrinkle reduction after 28 days



Photos of the Institute for Clinical Expertise (IEC) in Lyon, taken with the professional camera opposite:



Newtone Technologies



# SKIN PROTECTION (ANTI-AGEING / ANTI-UV)

A recent and promising innovation with proven effects

2023

## Brevet

Filing of a patent to protect the use of amoeba as a cosmetic ingredient

## In vitro studies

2024

## INCI

Inclusion of our cosmetic ingredient on the **INCI** (International Nomenclature of Cosmetics Ingredients) list of products, which means it can be marketed without further approval

## Clinical study

2025

## Label Cosmos approved

Label certifying the natural origin and eco-friendly ingredient

## MoU Metron – OBV

Registration and distribution in China

2025-26

## Development

- Business development agreement(s)
- Product testing and development : (formulation testing, range creation, etc.)
- Expansion of our active ingredient range
- China registration

2026-27

## Production & commercialisation

Production and marketing of the ingredient

# AMOÉBA x ORIENTAL BEAUTY VALLEY

## Signature of a Memorandum of Understanding with Metron Technology, a subsidiary of China's leading cosmetics company

### A strategic player in cosmetics in China

The Oriental Beauty Valley group is an industrial centre of excellence based in Shanghai, supported by the Chinese authorities.

It brings together more than 1,000 companies (including L'Oréal and Shiseido) in the field of beauty and well-being.



### Two major objectives

- ✓ On the regulatory front: approval of Amoéba's cosmetic ingredient in China (the world's 2nd largest cosmetics market, estimated at 85 billion euros)
- ✓ On the commercial front: distribution agreement with Chinese cosmetics groups

If approved in China, Amoéba's cosmetic ingredient could then be used worldwide, paving the way for future collaborations with international groups wanting to use the same formulas throughout the world.

# A MAJOR REINFORCEMENT FOR THE AMOÉBA BOARD

**A personality with multiple areas of expertise in the cosmetics and beauty industry**

## Charlotte FRANCERIES



## A major player in the world of cosmetics and communication

### ✓ 25 years with the L'Oréal group

- International Marketing Director Vichy
- International Marketing Director L'Oréal Paris skin care
- Biotherm International Managing Director
- Managing Director France Yves Saint Laurent Beauté
- International Managing Director Roger et Gallet
- Managing Director International L'Oréal Paris

### ✓ 7 years with the French subsidiary of the McCann Group (one of the world's leading advertising and communications agencies)

- Currently President of the French agency
- Worldwide Global Account Manager L'Oréal

# WHY INVEST ...

**The only company in the world dedicated to amoeba culture**

## Unique Technological Expertise

- ✓ The only company capable of cultivating an amoeba on an industrial scale.
- ✓ Exclusive technology enabling the amoeba to live and reproduce.

## Global Exclusivity

- ✓ The only private company in the world leveraging the positive applications of amoebas.
- ✓ An innovative alternative in a field where hundreds of companies focus on proteins, algae, and other resources...

## Leadership Position

- ✓ Competitive advantages driven by unique specialization and expertise.
- ✓ Several years ahead of potential competitors.

## Growth Potential

- ✓ Expanding fields from agriculture to cosmetics, with potential openings in other sectors, such as medical applications.
- ✓ Current facilities



... NOW

Financial markets rediscover Amoéba

- +133%


Positive share price trend over last 12 months
- +263%

Positive liquidity  
Evolution 6 months 2025 vs H2 2024
- €53m

Market capitalisation
- 3 analysts

KBC Sec. / Buy  
Euroland Corp. / Buy  
Portzamparc BNP Paribas / Hold

Amoéba share price from June 2024 to June 2025



Period : 25/06 - 31/12/2024		Period : 01/01 - 24/06/2025		Evolution
Securities volume	€20.4m	Securities volume	€20.4m	162%
EUR volume	€15,0m	EUR volume	€15,0m	289%

\* Moy; VWAP previous ten days





Amoéba



amoeba-nature.com



amoeba@actus.fr

# DISCLAIMER

References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question-and-answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein.

This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the multilateral trading facility of Euronext Growth, including, in particular, the risk factors set out in the universal registration document (the “URD”) filed with the French Financial Markets Authority (Autorité des marchés financiers) (the “AMF”) on April 18, 2023 under number D.23-0296, and in any other periodic report, which are available free of charge on the websites of the Company (<https://amoeba-nature.com>) and the AMF ([www.amf-france.org](http://www.amf-france.org)). Information and other data appearing in such publications, and certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages.

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained herein. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular, this document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such information is subject to change at any time. Neither the Company, its subsidiaries, directors, officers, employees, agents, affiliates nor its advisors, nor any other person is under any obligation to update the information, statements or opinions contained in this Presentation. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of the forward-looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation.

This Presentation does not constitute or form any part of any offer to sell, or the solicitation of an offer to buy or subscribe for, any shares or securities in the Company, in the United States or in any other jurisdiction.

All persons accessing this document are deemed to agree and comply with all the limitations and restrictions set out above.